...
首页> 外文期刊>Clinical colorectal cancer >Optimal Interval to Surgery After Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Systematic Review and Meta-analysis
【24h】

Optimal Interval to Surgery After Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Systematic Review and Meta-analysis

机译:直肠癌新辅助化学疗法后术后的最佳间隔:系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

This study aimed to evaluate the influence of a waiting interval of = 8 weeks between the end of preoperative neoadjuvant chemoradiotherapy (nCRT) and surgery on the outcomes of patients with locally advanced rectal cancer. We conducted a comprehensive literature review of retrospective and prospective studies from PubMed, Embase, and Cochrane Library databases to investigate the length of the preoperative nCRTesurgery waiting interval and outcomes in patients with locally advanced rectal cancer. The primary outcome measure was pathologic complete response (pCR) rate. Secondary outcome measures included overall survival, disease-free survival, operative time, and the incidence of local recurrence, postoperative complications, anastomotic leakage, and sphincter-preserving surgery. Standardized mean differences and risk ratios were calculated. Thirteen studies involving 19,652 patients were included. The meta-analysis demonstrated that pCR was significantly increased in patients with locally advanced rectal cancer and a waiting interval of = 8 weeks between preoperative nCRT and surgery compared to a waiting interval of 8 weeks, or a waiting interval of 8 weeks compared to = 8 weeks (risk ratio = 1.25; 95% confidence interval, 1.16-1.35; P .0001). There were no significant differences in overall survival, disease-free survival, operative time, or incidence of local recurrence, postoperative complications, or sphincter-preserving surgery. This study revealed that performing surgery after a waiting interval of = 8 weeks after the end of preoperative nCRT is safe and efficacious for patients with locally advanced rectal cancer, significantly improving pCR without increasing operative time or incidence of postoperative complications, compared to a waiting interval of = 8 weeks. (C) 2017 Elsevier Inc. All rights reserved.
机译:本研究旨在评估术前Neoadjuvant ChemoraMationerapy(NCRT)结束之间的等待间隔的影响和局部晚肠癌患者的患者的术后。我们对PubMed,Embase和Cochrane图书馆数据库进行了全面的文献综述,从PubMed,Embase和Cochrane库数据库中探讨了局部晚肠癌患者术前Ncrtesurgery等候间隔和结果的长度。主要结果措施是病理完全反应(PCR)率。二次结果措施包括整体存活,无病生存,手术时间,以及局部复发,术后并发症,吻合口泄漏和括约肌保存手术的发生率。计算标准化的平均差异和风险比。包括十三项涉及19,652名患者的研究。荟萃分析证明,在局部晚期直肠癌患者和等待区间的患者中,PCR显着增加,并且与术前NCRT和手术之间的等待区间相比< 8周或等待区间的&与& = 8周(风险比= 1.25; 95%置信区间,1.16-1.35; p& .0001)相比8周。整体存活,无病的存活,手术时间或局部复发,术后并发症或括约肌保存手术的发病均无显着差异。该研究表明,在术前NCR的等待间隔后进行手术,术前NCR的结束后,对于局部晚肠癌的患者,显着改善PCR,而不会增加术后并发症的发生率,而不是增加术后并发症的患者等待区间& = 8周。 (c)2017年Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号